Evidence map›Paper›PMID 41695475›Full record

ArticleTheranostics2026

A cochlea-sparing strategy for non-invasive control of intracranial schwannomas via peripheral irradiation and anti-PD-1 therapy enhanced by STING activation.

Zhenzhen Yin, Simeng Lu, Limeng Wu, Yao Sun, Day Caven Blake, Jie Chen, Lukas D Landegger, William Ho, Bingyu Xiu, Adam P Jones and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Zhenzhen YinEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Simeng LuEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Limeng WuEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Yao SunEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Day Caven BlakeEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Jie ChenEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Lukas D LandeggerDepartment of Otolaryngology - Head and Neck Surgery and Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, 94305, USA.
William HoEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Bingyu XiuEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Adam P JonesEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Alona MuzikanskyBiostatistics Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Helen A ShihDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Konstantina M StankovicDepartment of Otolaryngology - Head and Neck Surgery and Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA, 94305, USA.
Scott R PlotkinDepartment of Neurology and Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
Lei XuEdwin L. Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.

Funding

Co-Targeting IL-6 and EGFRsignaling for the Treatment of Schwannomatosis and Associated PainR01NS126187 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI JIANREN MAO, Lei Xu · 2023 to 2026
$1.8M
Targeting HMGB1 to improve hearing andenhance therapy for Vestibular SchwannomasR01DC020724 · NIDCD · MASSACHUSETTS GENERAL HOSPITAL · PI Konstantina M Stankovic, Lei Xu · 2023 to 2026
$1.8M
NIDCD NIH HHS R01 DC020724NINDS NIH HHS R01 NS126187
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Brain NeoplasmsCochleaImmune Checkpoint InhibitorsMembrane ProteinsNeurilemmomaAnimalscGAS-STING Signaling PathwayCombined Modality TherapyDisease Models, AnimalFemaleHearing LossHumansMiceProgrammed Cell Death 1 ReceptorSTING ProteinImmune Checkpoint InhibitorsMembrane ProteinsProgrammed Cell Death 1 ReceptorSting1 protein, mouseSTING Protein

Identifiers

PMID41695475
PMCPMC12905750

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.